Merck Moves Past 50-Day Average: How to Play MRK Stock Now

Merck (MRK) stock recently surpassed its 50-day Simple Moving Average, indicating a potential short-term bullish signal after a period of underperformance since mid-March. However, this technical strength is overshadowed by fundamental concerns, including the impending 2028 patent expiration and increasing competition for its top-selling drug, Keytruda, coupled with declining Gardasil sales in China and lowered 2025 guidance. These factors contribute to the stock's year-to-date underperformance and declining EPS estimates, suggesting significant near-term headwinds and long-term challenges despite Keytruda's continued growth and pipeline advancements.

Analysis

Merck's stock has recently crossed its 50-day simple moving average, a technical signal that contrasts sharply with its fundamental headwinds. The company's heavy reliance on Keytruda, which constitutes approximately 50% of its pharmaceutical sales, is a primary concern as it faces a patent cliff in 2028 and emerging competitive threats, notably from Summit Therapeutics' ivonescimab, which outperformed Keytruda in a Phase III NSCLC study in China. Compounding these concerns are significant operational issues with Gardasil, its second-largest product, where weak demand and high inventory levels in China have prompted a halt in shipments for the remainder of the year. This directly impacts the company's lowered 2025 guidance. While Merck is actively building its pipeline, which has nearly tripled since 2021 and includes promising new launches like Capvaxive and Winrevair, the market's focus remains on the nearer-term challenges. The stock's 17.7% year-to-date decline and downward revisions to 2025-2026 EPS estimates reflect this pessimistic outlook, rendering its low forward P/E ratio of 8.63 more of a reflection of risk than a clear value signal.

Key Decisions for Investors

• Despite a technically bullish cross of the 50-day moving average, investors should remain cautious due to significant fundamental pressures, including the halt of Gardasil shipments to China and the looming Keytruda patent cliff.
• Monitor key catalysts that could alter the risk profile, including the September FDA decision on the subcutaneous Keytruda formulation and the sales ramp-up of new products Winrevair and Capvaxive, which are critical for diversifying revenue.
• Given the stock's 17.7% year-to-date underperformance and declining EPS estimates, consider the current valuation as reflective of significant uncertainty, and evaluate whether the long-term pipeline potential sufficiently compensates for the near-term headwinds.